Role of SEREX-defined immunogenic wild-type cellular molecules in the development of tumor-specific immunity.
Ontology highlight
ABSTRACT: Recognition of altered self-antigens in tumor cells by lymphocytes forms the basis for antitumor immune responses. The effector cells in most experimental tumor systems are CD8(+) T cells that recognize MHC class I binding peptides derived from molecules with altered expression in tumor cells. Although the need for CD4(+) helper T cells in regulating CD8(+) T cells has been documented, their target epitopes and functional impact in antitumor responses remain unclear. We examined whether broadly expressed wild-type molecules in murine tumor cells eliciting humoral immunity contributed to the generation of CD8(+) T cells and protective antitumor immune responses to unrelated tumor-specific antigens [mutated ERK2 (mERK2) and c-erbB2/HER/neu (HER2)]. The immunogenic wild-type molecules, presum
SUBMITTER: Nishikawa H
PROVIDER: S-EPMC64723 | biostudies-literature | 2001 Dec
REPOSITORIES: biostudies-literature
ACCESS DATA